Tisagenlecleucel
Medication
>
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia which uses the body's own T cells to fight cancer.
Serious side effects occur in most patients. Wikipedia
AHFS/Drugs.com: Professional Drug Facts
ATC code: L01XL04 (WHO)
Elimination half-life: 16.8 days
Other names: CTL019, CART-19
Pregnancy category: : AU: C;
Pronunciation: tis" a jen" lek loo' se; /ˌtɪsədʒen'leklusel/
Routes of administration: Intravenous